Bayers' CEO Says Rapidly Shifting to Life Sciences

The transcript discusses the company's strategic direction towards life sciences, progress in the third quarter, and the divestiture of Covestro. It covers the animal health business, its market position, and potential collaboration with Eli Lilly. The Monsanto acquisition and regulatory compliance are addressed, along with the funding structure and optimization strategies. The company is focused on executing its plans while considering regulatory timelines and market conditions.

What challenges does the company face regarding regulatory approvals?

What factors are influencing the funding structure of the deal?

What is the company's perspective on the timelines for the Monsanto acquisition?